Gibson Dunn Advises Cogent Biosciences, Inc. on Upsized $230 Million Offering of Common Stock
Firm News | July 10, 2025
Gibson Dunn represented Cogent Biosciences, Inc. on an underwritten public offering of common stock that generated aggregate gross proceeds of approximately $230 million. J.P. Morgan Securities LLC, Leerink Partners LLC, and Guggenheim Securities, LLC acted as joint book-running managers for the offering, and LifeSci Capital LLC acted as lead manager.
Cogent is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company is based in Waltham, Massachusetts, and Boulder, Colorado.
Gibson Dunn regularly advises life sciences companies and investors on complex capital markets transactions in the biotechnology sector.